These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 10023504)
1. Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable? Mundo E; Bareggi SR; Pirola R; Bellodi L Biol Psychiatry; 1999 Feb; 45(3):290-4. PubMed ID: 10023504 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. Mundo E; Bianchi L; Bellodi L J Clin Psychopharmacol; 1997 Aug; 17(4):267-71. PubMed ID: 9241005 [TBL] [Abstract][Full Text] [Related]
3. Effects of acute intravenous clomipramine on obsessive-compulsive symptoms and response to chronic treatment. Mundo E; Bellodi L; Smeraldi E Biol Psychiatry; 1995 Oct; 38(8):525-31. PubMed ID: 8562664 [TBL] [Abstract][Full Text] [Related]
4. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. Koran LM; McElroy SL; Davidson JR; Rasmussen SA; Hollander E; Jenike MA J Clin Psychopharmacol; 1996 Apr; 16(2):121-9. PubMed ID: 8690827 [TBL] [Abstract][Full Text] [Related]
5. Clinical predictors of drug response in obsessive-compulsive disorder. Erzegovesi S; Cavallini MC; Cavedini P; Diaferia G; Locatelli M; Bellodi L J Clin Psychopharmacol; 2001 Oct; 21(5):488-92. PubMed ID: 11593074 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Piccinelli M; Pini S; Bellantuono C; Wilkinson G Br J Psychiatry; 1995 Apr; 166(4):424-43. PubMed ID: 7795913 [TBL] [Abstract][Full Text] [Related]
7. Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study. Mundo E; Bareggi SR; Pirola R; Bellodi L; Smeraldi E J Clin Psychopharmacol; 1997 Feb; 17(1):4-10. PubMed ID: 9004050 [TBL] [Abstract][Full Text] [Related]
8. Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions. Goodman WK; Ward H; Kablinger A; Murphy T J Clin Psychiatry; 1997; 58 Suppl 5():32-49. PubMed ID: 9184625 [TBL] [Abstract][Full Text] [Related]
9. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Milanfranchi A; Ravagli S; Lensi P; Marazziti D; Cassano GB Int Clin Psychopharmacol; 1997 May; 12(3):131-6. PubMed ID: 9248868 [TBL] [Abstract][Full Text] [Related]
10. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Jenike MA; Hyman S; Baer L; Holland A; Minichiello WE; Buttolph L; Summergrad P; Seymour R; Ricciardi J Am J Psychiatry; 1990 Sep; 147(9):1209-15. PubMed ID: 2143637 [TBL] [Abstract][Full Text] [Related]
11. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Fallon BA; Liebowitz MR; Campeas R; Schneier FR; Marshall R; Davies S; Goetz D; Klein DF Arch Gen Psychiatry; 1998 Oct; 55(10):918-24. PubMed ID: 9783563 [TBL] [Abstract][Full Text] [Related]
12. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. Pigott TA; Seay SM J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636 [TBL] [Abstract][Full Text] [Related]
13. Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder. Zitterl W; Aigner M; Stompe T; Zitterl-Eglseer K; Gutierrez-Lobos K; Wenzel T; Zettinig G; Hornik K; Pirker W; Thau K Neuropsychopharmacology; 2008 Dec; 33(13):3126-34. PubMed ID: 18354388 [TBL] [Abstract][Full Text] [Related]
14. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953 [TBL] [Abstract][Full Text] [Related]
15. Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment. Zohar J; Insel TR; Zohar-Kadouch RC; Hill JL; Murphy DL Arch Gen Psychiatry; 1988 Feb; 45(2):167-72. PubMed ID: 3276283 [TBL] [Abstract][Full Text] [Related]
16. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Mundo E; Guglielmo E; Bellodi L Int Clin Psychopharmacol; 1998 Sep; 13(5):219-24. PubMed ID: 9817627 [TBL] [Abstract][Full Text] [Related]
17. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291 [TBL] [Abstract][Full Text] [Related]
18. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Koran LM; Sallee FR; Pallanti S Am J Psychiatry; 1997 Mar; 154(3):396-401. PubMed ID: 9054789 [TBL] [Abstract][Full Text] [Related]
19. Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Mundo E; Maina G; Uslenghi C Int Clin Psychopharmacol; 2000 Mar; 15(2):69-76. PubMed ID: 10759337 [TBL] [Abstract][Full Text] [Related]